Jantoven and Vandetanib
Determining the interaction of Jantoven and Vandetanib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Cancer drugs such as vandetanib may alter the effects of warfarin. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience any unusual bleeding or bruising. Also seek immediate medical attention if you have potential signs and symptoms of blood clots such as chest pain, shortness of breath, difficulty breathing, coughing up blood, sudden loss of vision, and/or pain, redness or swelling in an arm or leg. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Theoretical concerns exist that chemotherapeutic agents may affect the anticoagulant effects of vitamin K antagonists. Anticoagulants are often administered to patients with cancer to reduce the risk of thrombosis.
MANAGEMENT: Given the potential for interaction, wide intraindividual variability in clinical response to anticoagulants, and the narrow therapeutic index of oral anticoagulants, European labeling recommends that patients should be closely monitored during concomitant therapy. The INR (International Normalized Ratio) should be checked more frequently. Patients should be advised to promptly report any signs of bleeding or blood clots.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Jantoven-Vanos
- Jantoven-Vanoxide-HC
- Jantoven-Vanquish
- Jantoven-Vanspar
- Jantoven-Vantas
- Jantoven-Vantin
- Vandetanib-Janumet
- Vandetanib-Janumet XR
- Vandetanib-Januvia
- Vandetanib-Japanese Encephalitis Vaccine
- Vandetanib-Japanese Encephalitis Virus Vaccine (Inactivated)
- Vandetanib-Japanese encephalitis virus vaccine SA14-14-2